**The British Dermatological Nursing Group (Limited by Guarantee)**
Report and unaudited Financial Statements
Year Ended
30 September 2024
**Company number** 07035369 **Charity number** 1133259
## **THE BRITISH DERMATOLOGICAL NURSING GROUP**
## **(Limited by Guarantee)**
**Annual report and unaudited financial statements for the year ended 30 September 2024**
|**Contents**||
|---|---|
|**Page:**||
|2|Report of the Trustees|
|8|Independent examiner’s report|
|9|Statement of financial activities|
|10|Balance sheet|
|11|Statement of cash flows|
|12|Notes forming part of the financial statements|
## **Directors/Trustees**
Elizabeth McGovern (President) Karen Stephen Elizabeth Lusted Valerie Anderson Pauline Stopford-Taylor Emmanuel Toni
## **Secretary and Registered Office**
Susan Maguire The Clubhouse 20 St Andrew Street London EC4A 3AG
## **Company number**
07035369
## **Charity number**
1133259
1
## **THE BRITISH DERMATOLOGICAL NURSING GROUP (Limited by Guarantee)**
## **Report of the Trustees for the year ended 30 September 2024**
The Trustees present their report and the unaudited financial statements for the year ended 30 September 2024.
## **The Trustees who served throughout the year were:**
Elizabeth McGovern (President) Melanie Sutherland (resigned 1[st] October 2024) Alberto Barea (resigned 1[st] October 2024) Rosemary Skrine (resigned 7[th] June 2024) Karen Stephen Elizabeth Lusted Valerie Anderson
## **Secretary**
Susan Maguire
## **Independent examiner**
Chesterton Consultancy Ltd 42 Abbotsbury Gardens Pinner Middlesex HA5 1SX
## **Solicitors**
B P Collins Collins House 32-38 Station Road Gerrards Cross Buckinghamshire SL9 8EL
2
## **THE BRITISH DERMATOLOGICAL NURSING GROUP (Limited by Guarantee)**
## **Report of the Trustees for the year ended 30 September 2024** _**(Continued)**_
## **Structure, Governance and Management Governing document**
The British Dermatological Nursing Group was incorporated on 30th September 2009 and is established as a company limited by guarantee and registered as a charity with the Charity Commission. The affairs of the Group are governed by its Memorandum and Articles of Association and managed by a Board of Directors who are Trustees of the Charity. The liability of each member in the event of the Group being wound up is limited to a sum not exceeding £1.
The British Dermatological Nursing Group was originally formed in 1989 as an unincorporated charity (No. 1077252). This charity ceased activity on the 31st May 2010 and its assets, totalling £262,898 were transferred to the new incorporated charity as of that date under a Transfer of Assets resolution dated 21st April 2010.
The directors of the company are also charity trustees for the purposes of charity law and under the company's Articles are known as Committee Members of the Charity. At a previous Annual General Meeting a vote was taken to change the articles of association allowing executive committee members to serve for up to 5 years on the committee and for there to be a maximum of seven Committee Members. No Committee Member shall be eligible for re-election for a period of 12 months from the date that his or her office comes to an end.
## **Objectives and Aims**
The unincorporated British Dermatological Nursing Group was formed in 1989 after recognising the need for a low cost educational platform to assist nurses in developing their skills and experience in dermatological nursing. The Group has a Constitution that is reviewed on an annual basis to ensure that it reflects the changing needs of the members as well as that of the Charities Commission. Any amendments to the Constitution are voted in by the Group at the Annual General Meeting.
The Group has referred to the guidance in the Charity Commission's general guidance on Public Benefit when reviewing its aims and objectives and in planning it’s future activities and the trustees believe that the activities undertaken are of clear benefit to the public and in accordance with the aims and objectives set. Specifically, the objects of the Group are to preserve and protect health and relieve sickness by maintaining and improving standards of practice in dermatological nursing for the public benefit.
## **Key management and remuneration**
The trustees consider the board of Trustees and the Chief Executive Officer as comprising the key management personnel of the charity in charge of directing and controlling the charity, and running and operating the charity on a day to day basis. Trustees are responsible for the management of The British Dermatological Nursing Group for which they receive no remuneration. The remuneration of the Chief Executive Officer is agreed by the Trustees when reviewing the previous year's annual accounts. The Chief Executive Officer’s remuneration is aligned to job roles and appropriate pay scales within both the private and NHS sectors.
## **Recruitment and appointment of new trustees**
It is the existing Trustees' responsibility to identify potential Trustees with appropriate skills and background from the Group's membership. Trustees are elected annually and reflect the national membership of the group. The Trustees are elected for a fixed term of office. Following this term, they retire from the position of Trustee.
3
## **THE BRITISH DERMATOLOGICAL NURSING GROUP (Limited by Guarantee)**
**Report of the Trustees for the year ended 30 September 2024** _**(Continued)**_
## **Risk management**
The British Dermatological Nursing Group has a comprehensive Risk Assessment Policy which categories the impact of the principal risks to the Group. The key risks are the continuance of both sufficient corporate sponsorship and the possible impact this could have on financial planning and management and the income generated with the annual conference event. Forthcoming events are planned in light of both of these sources of income. This is regularly discussed and monitored at Trustee Meetings which are attended by the Trustees and the Chief Executive Officer.
Potential corporate sponsors are investigated and the Trustees would consider diversification in other activities and sources of income if required.
## **Principle funding sources**
During the period the charity received corporate sponsorship of £450,940 (2023 - £380,427). In addition it received conference related income of £313,127 (2023 - £284,230) and subscriptions of £36,396 (2023 - £38,476).
## **Strategies**
Development of strategic aims for the group to:
- Ensure the structure of the BDNG is appropriate for its purpose;
- Ensure the BDNG maximises its influence and communicates to key stakeholders;
- Develop sound financial plans and practices to ensure income is sufficient to meet expenditure;
- Provide appropriate educational and practice development to members;
- Ensure the BDNG website meets the needs of its members;
- Ensure the BDNG meets the needs of its existing and future membership.
Through the development of sub groups, the Group continues to offer peer support and information sharing. These sub groups report directly to the Committee and the Chair of each of these groups is a co-opted member of the Committee.
The Group continues to have representation of various external groups from within the Committee and also identified Group members. These representatives report directly to the Committee.
4
**THE BRITISH DERMATOLOGICAL NURSING GROUP (Limited by Guarantee)**
## **Report of the Trustees for the year ended 30 September 2024** _**(Continued)**_
## **Achievements and Performance**
## **Charitable Activities**
This report outlines the key activities undertaken by the British Dermatological Nursing Group (BDNG) over the past year. These initiatives have strengthened our commitment to dermatology nursing and professional development while expanding our influence within the field.
The BDNG provided financial support for the Burma Skin Initiative Spirit of Partnership garden at the prestigious Chelsea Flower Show. This initiative raised awareness of skin health and dermatological conditions in an innovative and engaging manner, enhancing public understanding of dermatology and role of dermatology nurses. The BDNG successfully hosted it’s 33[rd] Annual Conference in September 2024 attended by 450 delegates, providing an enriching platform for education, networking, and knowledge sharing. The conference featured leading speakers, insightful discussions, and interactive workshops, contributing to the professional growth of dermatology nurses and allied professionals.
The BDNG organised and delivered two additional educational events in Brighton and Manchester with each event attracting over 90 delegates.
In an effort to modernise and align our publication with current trends, the BDNG undertook a comprehensive rebranding of its journal. The refreshed design and content strategy aim to enhance readability, accessibility and engagement, ensuring that our members receive high-quality and relevant information.
The BDNG worked closely with other organisations within the dermatology community. In particular, the BDNG collaborated with the British Association of Dermatologists (BAD) and Medicines and Healthcare products Regulatory Agency (MHRA) to support the development of updated guidelines on isotretinoin use. This collaboration ensured that best practices were followed in clinical settings, enhancing patient safety and improving treatment outcomes for individuals with severe acne.
During the year the BDNG hosted a successful awards ceremony celebrating excellence in dermatology nursing. The event recognized outstanding contributions within the profession, inspiring members and highlighting innovative practices that advance patient care.
To support our growing initiatives, BDNG has welcomed four new members of staff, an Event Manager, an In Person Events Lead, a Membership and Internation Lead and an Education Nurse. This expansion strengthens our capacity to deliver high-quality services, enhance member engagement and continue our mission of advancing dermatology nursing.
## **Future Plans**
The BDNG continues to expand its reach and impact within the dermatology community. Our key initiatives aimed at enhancing professional education, fostering collaboration and elevating the visibility of our journal. Our future plans include increasing in-person educational events and webinars, hosting a flagship event for dermatology nurses, pursuing PubMed listing for the BDNG Journal, and engaging in international dermatology forums.
The BDNG will strengthen professional development opportunities by increasing face-to-face educational events and virtual learning sessions. We will hold at least four in-person education events to ensure accessibility to members across the UK collaborating with leading experts to enhance the quality and relevance of educational content to improve knowledge and skills among dermatology nurses and stronger networking opportunities within the dermatology nursing community.
5
## **THE BRITISH DERMATOLOGICAL NURSING GROUP (Limited by Guarantee)**
**Report of the Trustees for the year ended 30 September 2024** _**(Continued)**_
We will elevate the BDNG Journal's academic credibility by securing inclusion in PubMed. Working closely with journal editors to align content quality with PubMed’s indexing criteria and increasing the number of peerreviewed articles and original research submissions. This will lead to enhanced visibility and citation rate for the BDNG Journal and strengthened reputation of BDNG as a thought leader in dermatology nursing.
Representatives from the BDNG have been invited to attend the International League of Dermatological Society (ILDS) World Skin Summit in 2025. This will enable to BDNG to establish connections with international dermatology associations.
The BDNG remains committed to advancing dermatology nursing through expanded educational initiatives, strengthened academic recognition, and international engagement. By implementing these plans, we aim to enhance the professional development of dermatology nurses, increase the reach of our journal, and solidify BDNG’s position as a leader in dermatology nursing education and advocacy.
## **Investment policy and Objectives**
The constitution authorises the trustees to apply the assets and property of the Charity solely towards the promotion and purpose of The British Nursing Dermatological Group as laid down in the constitution.
## **Reserves Policy**
Any funds provided to the British Dermatological Nursing Group for a specific purpose are classed as a restricted reserve. Trustees are resolved to limit spending each year to an amount considered to balance the interest of the current and future beneficiaries of the Group's work.
In light of the recent pandemic, the Trustees continue to adopt a more cautious policy of retaining funds, thus protecting the Group's core activities in the event of a shortfall in income. Furthermore the trustees intend to continue use any excess reserves to focus on a number of new initiatives, as reviewed in the Future Plans section of this report.
Unrestricted reserves at the balance sheet date totalled £588,521 (2023 - £605,910) and restricted reserves of £Nil (2023 - £Nil).
## **Qualifying 3[rd] Party Indemnity Provisions**
The charitable company has granted an indemnity to its trustees against liability in respect of actions brought by third parties, subject to the conditions set out in the Companies Act 2006. Such qualifying third party indemnity provision remains in force as at the date of approving the Trustees’ Report.
6
## **THE BRITISH DERMATOLOGICAL NURSING GROUP**
## **(Limited by Guarantee)**
**Report of the Trustees for the year ended 30 September 2024** _**(Continued)**_
## **Statement of Trustees’ Responsibilities**
The trustees (who are also directors of The British Dermatological Nursing Group for the purposes of company law) are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year. In preparing those financial statements, the trustees are required to:
- select suitable accounting policies and then apply them consistently,
- observe the methods and principles in the Charities SORP,
- make judgements and estimates that are reasonable and prudent,
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on a going concern basis unless it is inappropriate to presume that the charitable company will continue in business.
The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime within Part 15 of the Companies Act 2006.
Signed on behalf of Trustees
## **Elizabeth McGovern Chair**
Dated
7
## **THE BRITISH DERMATOLOGICAL NURSING GROUP (Limited by Guarantee)**
## **Independent Examiners Report to the members of The British Dermatological Nursing Group**
## **_________________________________________________________________________________**
I report to the charity trustees on my examination of the accounts of The British Dermatological Nursing Group for the year ended 30[th] September 2024.
## **Responsibilities and basis of report**
As the charity’s trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (‘the 2006 Act’).
Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity’s accounts as carried out under section 145 of the Charities Act 2011 (‘the 2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.
## **Independent examiner's statement**
Since the Company’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Chartered Institute of Management Accountants, which is one of the listed bodies.
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
- (1) accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
- (2) the accounts do not accord with those records; or
- (3) the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a ‘true and fair view which is not a matter considered as part of an independent examination; or
- (4) the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Date:
**Graham Bolton F.C.M.A. For and on behalf of Chesterton Consultancy Ltd** Management Accountant
42 Abbotsbury Gardens Pinner Middlesex HA5 1SX
8
## **THE BRITISH DERMATOLOGICAL NURSING GROUP**
## **(Limited by Guarantee)**
**Statement of financial activities (incorporating an income and expenditure account) for the year ended 30 September 2024**
|**Unrestricted Restricted**
**Funds**
**Funds**
**Note**
**£**
**£**
**Income and endowments from:**
Corporate sponsorship
**450,940**
**-**
Subscriptions
**36,396**
**-**
Investments
**2**
**505**
**-**
**Charitable activities**
Educational meeting attendance fees
**20,310**
**-**
Annual Conference
**313,127**
**-**
_______
_______
**Total income**
**821,278**
**0**
_______
_______
**Expenditure on:**
**Raising funds**
Fundraising costs
**3**
**122,439**
-
**Charitable activities**_:_
Education and educational meetings
**4**
**666,228**
-
**Donations**
**50,000**
**-**
_______
_______
**Total expenditure**
**838,667**
**0**
**Net (expenditure)/income**
**(17,389)**
**0**
Resources b/fwd
**605,910**
**-**
______
_______
**Balance as at 30 September 2024**
**588,521**
**0**|**2024**
**2023**
**Total**
**Total**
**£**
**£**
**450,940**
380,427
**36,396**
38,476
**505**
341
**20,310**
23,976
**313,127**
284,230
_______
_______
**821,278**
727,450
_______
_______
**122,439**
96,970
**666,228**
680,926
**50,000**
**-**
_______
______
**838,667**
777,896
**(17,389)**
(50,446)
**605,910**
656,356
______
______
**588,521**
605,910|
|---|---|
All amounts relate to continuing activities. All gains and losses recognised in the year are included above.
The notes on pages 12 to 17 form part of these financial statements.
9
## **THE BRITISH DERMATOLOGICAL NURSING GROUP (Limited by Guarantee)**
## **Balance sheet at 30 September 2024**
|**Unrestricted Restricted**
**Funds**
**Funds**
**Note**
**£**
**£**
**Fixed assets**
Tangible assets
**9**
**6,726**
-
**Current assets**
Debtors
**10**
**414,701**
-
Cash and bank balances
**424,433**
**-**
**_______**
**_______**
**839,134**
**0**
**Creditors: amounts falling**
**within one year**
**11**
**(257,339)**
**-**
**_______**
**_______**
**Net current assets**
**581,795**
**0**
**_______**
**_______**
**Net assets**
**588,521**
**0**
_______
______
**Financed by:**
Unrestricted funds
**12**
Restricted Funds|**2024**
**Total**
**£**
**6,726**
**414,701**
**424,433**
**_______**
**839,134**
**(257,339)**
**_______**
**581,795**
**_______**
**588,521**
_______
**588,521**
**0**
**_______**
**588,521**|**2023**
**Total**
**£**
7,992
257,399
449,164
**_______**
706,563
(108,645)
**_______**
597,918
**_______**
605,910
_______
605,910
0
**______**
605,910|
|---|---|---|
_______ ______
For the year ending 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006. They also acknowledge their responsibility for preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company
These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved and authorised for issue on and signed on its behalf by:
## __________________ Elizabeth McGovern **Trustee (Chair)**
The notes on pages 12 to 17 form part of these financial statements.
## **Company Registration No.** 07035369
10
## **THE BRITISH DERMATOLOGICAL NURSING GROUP (Limited by Guarantee)**
## **Statement of Cash Flows for the year ended 30 September 2024**
||**2024**|**2023**|
|---|---|---|
||**£**|**£**|
|_=_|||
|**Cash flows/(Loss) from operating activities**|||
|Net (expenditure)/income for the year|**(17,389)**|(50,446)|
|**Add back depreciation**|**4,227**|3,250|
||**______**|**______**|
||**(13,162)**|(47,196)|
|**Purchase of fixed assets**|**(2,961)**|(4,224)|
|Adjustments for:|||
|Interest receivable|**(505)**|(341)|
|Decrease/(increase) in debtors|**(157,302)**|(123,453)|
|Increase/(decrease) in creditors|**148,694**|(40,431)|
||**_______**|**_______**|
|**Net cash generated/(used) in operating activities**|**(25,236)**|(215,645)|
|**Cash flows from investing activities**|||
|Interest received from investments|**505**|341|
||**_______**|**_______**|
|**Net cash (used in) / provided by investing activities**|**505**|341|
||**_______**|**_______**|
|**Cash flows from financing activities**|**-**|**-**|
||**_______**|**_______**|
|**Change in cash and cash equivalents in the reporting period**|**(24,731)**|(215,304)|
|Cash and cash equivalents at the beginning of the year|**449,164**|
664,468
|
||**_______**|**_______**|
|**Cash and cash equivalents at the end of the year**|**424,433**|449,164|
||**_______**|_______|
11
## **THE BRITISH DERMATOLOGICAL NURSING GROUP (Limited by Guarantee)**
## **Notes forming part of the financial statements for the year ended 30 September 2024**
## **1 Accounting policies**
The British Dermatological Nursing Group is a company limited by guarantee, domiciled and incorporated in England and Wales. The registered office is The Clubhouse, 20 St Andrew Street, London. EC4A 3AG.
## **Basis of accounting**
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention
The financial statements are prepared in sterling, which is the functional currency of the entity. Monetary amounts in these financial statements are rounded to the nearest pound.
## **Going Concern**
The trustees assess whether the use of going concern is appropriate i.e. whether there are any material uncertainties related to events or conditions that may cast significant doubt on the ability of the company to continue as a going concern.
The trustees make this assessment in respect of a period of one year from the date of the approval of the financial statements and have concluded that there are no material uncertainties about the charity's ability to continue.
.
## **Income**
Subscriptions, sponsorship and other income is accounted for in the year in which it is receivable. Income from attendance fees for educational meetings is recognised in the year in which they are held.
Where a sponsorship has been specified as relating to a future accounting period, the income is deferred until that period. All income deferred in the previous year has been recognised in the current year.
## **Income from investments**
Bank interest is accounted for when received.
## **Expenditure**
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to the expenditure. Expenses are accounted for on an accruals basis.
12
**THE BRITISH DERMATOLOGICAL NURSING GROUP (Limited by Guarantee)**
## **Notes forming part of the financial statements for the year ended 30 September 2024** _**(Continued)**_
## **1 Accounting policies (continued)**
_Costs of generating funds_ comprise of those costs directly attributable to generating sponsorship income.
_Charitable activities_ include all expenditure incurred in pursuance of the Society’s objectives.
_Governance costs_ comprise of all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to the preparation and examination of the financial statements, other professional and legal fees.
_Support costs_ include general administrative costs and are apportioned to appropriate expense categories on a percentage of total cost basis.
## **Tangible fixed assets and Depreciation**
Tangible fixed assets are included at cost. Depreciation is provided to write off the cost, less estimated residual values, of all tangible fixed assets, evenly over their expected useful lives. It is calculated at the following rates:
Computer equipment - 25% per annum straight line Plant & machinery - 20% per annum straight line
## **Financial instruments**
_Cash and cash equivalents_ comprise cash at banks and in hand, including short term deposits with a maturity date of up to 12 months.
## _Debtors and Creditors_
Debtors and creditors receivable or payable within one year of the reporting date are carried at their transaction price.
## **Funds**
_Unrestricted funds_ comprise of the accumulated excess of incoming resources over resources expended on the Statement of Financial Activities. They are available for use at the discretion of the Trustees in furtherance of the general objectives of the Society.
_Restricted funds_ comprise of the accumulated excess of incoming resources over resources expended on the Statement of Financial Activities and are only available for their specified use.
## **Taxation**
No provision has been made for taxation as the Society’s status renders it exempt from UK direct taxation.
13
**THE BRITISH DERMATOLOGICAL NURSING GROUP (Limited by Guarantee)**
**Notes forming part of the financial statements for the year ended 30 September 2024** _**(Continued)**_
## **1 Accounting policies (continued)**
## **Judgements and key sources of estimation uncertainty**
In the application of the charity’s accounting policies, the trustees are required to make judgements, estimates and assumptions that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant.
The judgement that management has made in the process of applying the charity’s accounting policies which has the most significant effect on the amounts recognised in the accounts is the allocation of support costs across activities.
## **2 Investment income**
|**2**|**Investment income**|||
|---|---|---|---|
|||**2024**|**2023**|
|||**£**|**£**|
||Interest on cash deposits|**505**|341|
|||||
|||______|______|
|**3**|**Costs of generating funds**|||
|||**2024**|**2023**|
|||**£**|**£**|
||External fundraising costs|**75,234**|58,732|
||Support costs|**47,205**|38,238|
|||______|______|
|||**122,439**|96,970|
|||______|_____|
|**4**|**Charitable activities**|||
|||**2024**|**2023**|
|||**£**|**£**|
||Educational meeting costs|**44,501**|79,605|
||Conference costs|**172,292**|181,826|
||Journal costs|**67,027**|65,665|
||Awards|**94,830**|69,722|
||Other charitable costs|**30,722**|16,587|
||Support costs|**256,856**|267,521|
|||_______|______|
|||**666,228**
_______|680,926
______|
14
## **THE BRITISH DERMATOLOGICAL NURSING GROUP**
## **(Limited by Guarantee)**
**Notes forming part of the financial statements for the year ended 30 September 2024** _**(Continued)**_
|**5**
**Support costs**
Salaries and related payroll costs
Travel & subsistence
Office expenses
Software development and subscriptions
Rent & premises costs
Depreciation
Governance costs (see Note 6)
Apportioned to:
Costs of generating funds
Charitable activities
**6**
**Analysis of governance costs**
Independent examiners remuneration is broken down as follows:
Independent examination of the financial statements
Other governance costs include:
Accountancy
Legal & professional fees|**5**
**Support costs**
Salaries and related payroll costs
Travel & subsistence
Office expenses
Software development and subscriptions
Rent & premises costs
Depreciation
Governance costs (see Note 6)
Apportioned to:
Costs of generating funds
Charitable activities
**6**
**Analysis of governance costs**
Independent examiners remuneration is broken down as follows:
Independent examination of the financial statements
Other governance costs include:
Accountancy
Legal & professional fees|
|---|---|
||_|
15
## **THE BRITISH DERMATOLOGICAL NURSING GROUP (Limited by Guarantee)**
**Notes forming part of the financial statements for the year ended 30 September 2024** _**(Continued)**_
## **7 Trustees and other employees**
There were no trustees' remuneration or other benefits for the year ended 30th September 2024 nor for the year ended 30th September 2023.
Trustees had expenses reimbursed totalling £13,537 (2023 - £21,000) in respect of travel and subsistence.
No other related party transactions took place in the year that require disclosure.
|**8**|**Staff Costs**|**2024**|**2023**|
|---|---|---|---|
||Wages and salaries|**187,768**|138,481|
||Social security costs|**13,570**|9,187|
||Pension costs|**4,104**|3,690|
|||______|______|
|||**205,442**|151,358|
|||||
|||______|______|
||The average number of employees during the year was as follows:|||
|||**2024**|**2023**|
||Administration and education|6|4|
|||||
|||______|______|
||The number of employees whose employee benefits (excluding employer pension costs) exceeded|||
||£60,000 was:|||
|||**2024**|**2023**|
||£60,000 - £70,000|1|1|
|||||
|||______|______|
|**9**|**Fixed assets**||**Computer software and**|
||||**Office equipment**|
||||**£**|
||_Cost_|||
||At 1 November 2023||16,042|
||Additions||2,961|
||Disposals||(1,770)|
||||______|
||At 30 September 2024||**17,233**|
||||______|
||_Depreciation_|||
||At 1 November 2023||8,050|
||Provided for the year||4,227|
||Written back on disposal||(1,770)|
||||______|
||At 30 September 2024||**10,507**|
||||______|
||_Net book value_|||
||At 30 September 2024||**6,726**|
||||____|
||At 30 September 2023||7,992|
||||____|
16
## **THE BRITISH DERMATOLOGICAL NURSING GROUP**
## **(Limited by Guarantee)**
## **Notes forming part of the financial statements for the year ended 30 September 2024** _**(Continued)**_
|**10**|**Debtors**|||||
|---|---|---|---|---|---|
|||||**2024**|**2023**|
|||||**£**|**£**|
||Trade debtors|||**392,210**|199,192|
||Other debtors|||**-**|2,000|
||Prepayments and accrued income|||**22,491**|56,207|
|||||______|______|
|||||**414,701**|257,399|
|||||||
|||||______|______|
|**11**|**Creditors: amounts falling due within one year**|||||
|||||**2024**|**2023**|
|||||**£**|**£**|
||Trade creditors|||**47,525**|30,346|
||Other creditors|||**134,067**|44,366|
||Accruals|||**26,746**|17,113|
||Taxation|||**49,001**|16,820|
|||||______|______|
|||||**257,339**|106,645|
|||||||
|||||______|______|
|**12**|**Unrestricted funds**|||||
||||||**Balance**|
|||**Balance**|**Incoming**|**Outgoing**|**30 Sep**|
|||**b/fwd**|**Resources**|**Resources**|**2024**|
|||**£**|**£**|**£**|**£**|
||**Unrestricted funds**|||||
||General fund|**605,910**|**821,278**|**(838,667)**|**588,521**|
|||**_______**|**_______**|**_______**|**______**|
||**Total Funds**|**605,910**
_______|**821,278**
_______|**(838,667**
_______|**588,521**
______|
17